HONG KONG – Xuanzhu (Shijiazhuang) Biopharmaceutical Co. Ltd., Beijing-based Sihuan Pharmaceutical Holdings Group Ltd.’s innovative drug R&D platform, has secured ¥800 million (US$117.2 million) in series A funding from the State Development and Investment Corp. (SDIC). CMG-SDIC Capital Co. Ltd. (CMG-SDIC) invested the entire ¥800 million, giving SDIC an 18.6% equity interest in the platform, a company spokesperson told BioWorld.

A nearly $2 billion global development and commercialization deal with Abbvie Inc. and a $418 million private placement have bolstered I-Mab Biopharma Co. Ltd.’s position globally. I-Mab framed the deal as being the largest out-licensing and global partnership transaction ever executed by a China-based biotech. Abbvie and I-Mab plan to develop and commercialize the anti-CD47 monoclonal antibody lemzoparlimab for treating multiple cancers globally, with the exception of China. Lemzoparlimab, also called TJC-4, is Shanghai-based I-Mab’s discovery and its lead cancer therapy. The company will get an up-front $180 million by licensing the highly differentiated antibody to Abbvie, along with a $20 million milestone payment based on phase I results.

A nearly $2 billion global development and commercialization deal with Abbvie Inc. and a $418 million private placement have bolstered I-Mab Biopharma Co. Ltd.’s position globally. I-Mab framed the deal as being the largest out-licensing and global partnership transaction ever executed by a China-based biotech.

HONG KONG – Xuanzhu (Shijiazhuang) Biopharmaceutical Co. Ltd., Beijing-based Sihuan Pharmaceutical Holdings Group Ltd.’s innovative drug R&D platform, has secured ¥800 million (US$117.2 million) in series A funding from the State Development and Investment Corp. (SDIC).

Bright days are ahead for China’s biopharmaceutical sector, which is getting a reset from the efforts to tackle COVID-19 through innovation and advancements. “I'm consciously optimistic about the fact that cross-border deals will continue,” Stella Xu, managing director, Quan Capital, from Shanghai, China said during a panel discussion at the Chinabio Partnering Forum.

HONG KONG – Tokyo-based Chugai Pharmaceutical Co. Ltd. has launched a subcutaneous injection  of Enspryng (satralizumab) in Japan to prevent relapses of neuromyelitis optica spectrum disorder (NMOSD), including neuromyelitis optica (NMO).

LONDON – Ion Beam Applications SA (IBA) has taken a giant step into China, sealing a €100 million-plus (US$118.2 million) licensing deal with a local company to manufacture, install and maintain its proton beam cancer therapy systems.

While the COVID-19 pandemic has brought disruptions to R&D, market activities in the biopharmaceutical sector have remained active during the first half of this year in China. Venture capital investments, IPOs and partnering activity showed upward trends, except for M&A activity, which has declined for two years.

Ever since the Hong Kong Stock Exchange (HKEX) overhauled its listing rules to welcome pre-revenue biotech companies in April 2018, Hong Kong has become the largest biotech fundraising hub in Asia, and the second largest in the world after Nasdaq, HKEX executives said Tuesday at the bourse’s biotech summit. The biotech IPO pipeline continues to grow and pre-revenue companies are more accepted into the city’s financial system.

HONG KONG – Tokyo-based Chugai Pharmaceutical Co. Ltd. has launched a subcutaneous injection  of Enspryng (satralizumab) in Japan to prevent relapses of neuromyelitis optica spectrum disorder (NMOSD), including neuromyelitis optica (NMO).